Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. Glenmark’s Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC.
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market achieved annual sales of around $67.6 million. Glenmark’s Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
